

## **6. Literaturverzeichnis**

1. Agha A, Schluter H, Konig S, Biel K, Tepel M, Zidek W. A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives. *J Vasc Res.* 1992;29:281-9.
2. Association AH. Heart and Stroke Statistical Update. *Internetseiten:*  
[http://amhrt.org/downloadable/heart/10148328094661013190990123HS\\_State\\_02.pdf](http://amhrt.org/downloadable/heart/10148328094661013190990123HS_State_02.pdf). 2002.
3. Avila DM, Robinson AK, Kaushal V, Barnes LD. A paradoxical increase of a metabolite upon increased expression of its catabolic enzyme: the case of diadenosine tetraphosphate (Ap4A) and Ap4A phosphorylase I in *Saccharomyces cerevisiae*. *J Bacteriol.* 1991;173:7875-80.
4. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. *N Engl J Med.* 1997;336:1276-82.
5. Burnstock G. *A basic for distinguishing two types of purinergic receptors*. Raven, New York; 1978.
6. Burnstock G. P2 purinoceptors: historical perspective and classification. *Ciba Found Symp.* 1996;198:1-28.
7. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. *Can J Cardiol.* 2002;18:371-9.
8. Cinkilic O, King BF, van der Giet M, Schluter H, Zidek W, Burnstock G. Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety. *J Pharmacol Exp Ther.* 2001;299:131-6.
9. Classen M, Diehl V, Kochsiek K. *Innere Medizin.* . 1994:1084-95.

10. D'Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham study. *Am Heart J*. 2000;139:272-81.
11. Davies G, MacAllister RJ, Bogle RG, Vallance P. Effect of diadenosine phosphates on human umbilical vessels: novel platelet-derived vasoconstrictors. *Br J Clin Pharmacol*. 1995;40:170-2.
12. Davies MJ. The composition of coronary-artery plaques. *N Engl J Med*. 1997;336:1312-4.
13. Deutsche Gesellschaft für Kardiologie- H-uK. Leitlinie Koronare Herzkrankheit/ Angina pectoris. *Internetseiten: <http://www.dgkardio.de/leitlinien/LeitlinienKoronareHerzkrankheit.pdf>*. 1998.
14. Evans RJ, Lewis C, Buell G, Valera S, North RA, Surprenant A. Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors). *Mol Pharmacol*. 1995;48:178-83.
15. Feigl EO. The paradox of adrenergic coronary vasoconstriction. *Circulation*. 1987;76:737-45.
16. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature*. 1980;288:373-6.
17. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. *Circulation*. 1994;90:2126-46.
18. Gasmi L, McLennan AG, Edwards SW. Neutrophil apoptosis is delayed by the diadenosine polyphosphates, Ap5A and Ap6A: synergism with granulocyte-macrophage colony-stimulating factor. *Br J Haematol*. 1996;95:637-9.
19. Golino P, Piscione F, Willerson JT, Cappelli-Bigazzi M, Focaccio A, Villari B, Indolfi C, Russolillo E, Condorelli

- M, Chiariello M. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. *N Engl J Med*. 1991;324:641-8.
20. Gordon JB, Ganz P, Nabel EG, Fish RD, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. *J Clin Invest*. 1989;83:1946-52.
21. Hansmann G, Ihling C, Pieske B, Bultmann R. Nucleotide-evoked relaxation of human coronary artery. *Eur J Pharmacol*. 1998;359:59-67.
22. Harden TK, Boyer JL, Nicholas RA. P2-purinergic receptors: subtype-associated signaling responses and structure. *Annu Rev Pharmacol Toxicol*. 1995;35:541-79.
23. Heidenreich S, Tepel M, Schluter H, Harrach B, Zidek W. Regulation of rat mesangial cell growth by diadenosine phosphates. *J Clin Invest*. 1995;95:2862-7.
24. Hohage H, Reinhardt C, Borucki U, Enck G, Schluter H, Schlatter E, Zidek W. Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats. *J Am Soc Nephrol*. 1996;7:1216-22.
25. Holmsen H, Dangelmaier CA. Measurement of secretion of adenine nucleotides. *Methods Enzymol*. 1989;169:195-205.
26. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. *Circ Res*. 1987;61:866-79.
27. Jankowski J, Potthoff W, van der Giet M, Tepel M, Zidek W, Schluter H. High-performance liquid chromatographic assay

- of the diadenosine polyphosphates in human platelets. *Anal Biochem.* 1999;269:72-8.
28. Jovanovic A, Jovanovic S, Mays DC, Lipsky JJ, Terzic A. Diadenosine 5',5"-P<sub>1</sub>,P<sub>5</sub>-pentaphosphate harbors the properties of a signaling molecule in the heart. *FEBS Lett.* 1998;423:314-8.
  29. Kaiser RA, Buxton IL. Nucleotide-mediated relaxation in guinea-pig aorta: selective inhibition by MRS2179. *Br J Pharmacol.* 2002;135:537-45.
  30. Kelm M, Feelisch M, Spahr R, Piper HM, Noack E, Schrader J. Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells. *Biochem Biophys Res Commun.* 1988;154:236-44.
  31. Kikuta Y, Sekine A, Tezuka S, Okada K, Yamaura T, Nakajima H. Intravenous diadenosine tetraphosphate in dogs. Cardiovascular effects and influence on blood gases. *Acta Anaesthesiol Scand.* 1994;38:284-8.
  32. Korchazhkina O, Wright G, Exley C. Intravascular ATP and coronary vasodilation in the isolated working rat heart. *Br J Pharmacol.* 1999;127:701-8.
  33. Kunapuli SP, Daniel JL. P<sub>2</sub> receptor subtypes in the cardiovascular system. *Biochem J.* 1998;336:513-23.
  34. Lever AF. Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels? *J Hypertens.* 1986;4:515-24.
  35. Lewis CJ, Gitterman DP, Schluter H, Evans RJ. Effects of diadenosine polyphosphates (Ap(n)As) and adenosine polyphospho guanosines (Ap(n)Gs) on rat mesenteric artery P<sub>2</sub>X receptor ion channels. *Br J Pharmacol.* 2000;129:124-30.
  36. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced

- by acetylcholine in atherosclerotic coronary arteries. *N Engl J Med*. 1986;315:1046-51.
37. Luo J, Jankowski J, Knobloch M, Van der Giet M, Gardanis K, Russ T, Vahlensieck U, Neumann J, Schmitz W, Tepel M, Deng MC, Zidek W, Schluter H. Identification and characterization of diadenosine 5',5''-P<sub>1</sub>,P<sub>2</sub> - diphosphate and diadenosine 5',5''-P<sub>1</sub>,P<sub>3</sub>-triphosphate in human myocardial tissue. *Faseb J*. 1999;13:695-705.
  38. Luthje J, Ogilvie A. Catabolism of Ap<sub>4</sub>A and Ap<sub>3</sub>A in whole blood. The dinucleotides are long-lived signal molecules in the blood ending up as intracellular ATP in the erythrocytes. *Eur J Biochem*. 1988;173:241-5.
  39. Malmsjo M, Hou M, Harden TK, Pendergast W, Pantev E, Edvinsson L, Erlinge D. Characterization of contractile P<sub>2</sub> receptors in human coronary arteries by use of the stable pyrimidines uridine 5'-O-thiodiphosphate and uridine 5'-O-3-thiotriphosphate. *J Pharmacol Exp Ther*. 2000;293:755-60.
  40. Marx N, Neumann FJ, Zohlhofer D, Dickfeld T, Fischer A, Heimerl S, Schomig A. Enhancement of monocyte procoagulant activity by adhesion on vascular smooth muscle cells and intercellular adhesion molecule-1-transfected Chinese hamster ovary cells. *Circulation*. 1998;98:906-11.
  41. Meyer J. *Koronare Herzkrankheit und Herzinfarkt*. Berlin, Heidelberg, New York,: Springer Verlag; 1996.
  42. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacol Rev*. 1991;43:109-42.
  43. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. *N Engl J Med*. 1993;329:2002-12.
  44. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and

- tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. *Circulation*. 1996;94:3090-7.
45. Motte S, Communi D, Piroton S, Boeynaems JM. Involvement of multiple receptors in the actions of extracellular ATP: the example of vascular endothelial cells. *Int J Biochem Cell Biol*. 1995;27:1-7.
  46. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. *Circulation*. 1988;77:43-52.
  47. Neumann FJ, Ott I, Gawaz M, Puchner G, Schomig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. *J Am Coll Cardiol*. 1996;27:819-24.
  48. Neumann J, Meissner A, Boknik P, Gombosova I, Knapp J, Luss H, Muller FU, Schluter H, Zidek W, Rolf N, Van Aken H, Vahlensieck U, Schmitz W. Inotropic effects of diadenosine tetraphosphate in isolated canine cardiac preparations. *J Cardiovasc Pharmacol*. 1999;33:151-6.
  49. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest*. 1993;91:2546-51.
  50. Pagano PJ, Lin L, Sessa WC, Nasjletti A. Arachidonic acid elicits endothelium-dependent release from the rabbit aorta of a constrictor prostanoid resembling prostaglandin endoperoxides. *Circ Res*. 1991;69:396-405.
  51. Palfi Z, Suranyi G, Borbely G. Alterations in the accumulation of adenylylated nucleotides in heavy-metal-ion-stressed and heat-stressed *Synechococcus* sp. strain PCC 6301, a cyanobacterium, in light and dark. *Biochem J*. 1991;276:487-91.

52. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature*. 1987;327:524-6.
53. Patel K, Barnes A, Camacho J, Paterson C, Boughtflower R, Cousens D, Marshall F. Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. *Eur J Pharmacol*. 2001;430:203-10.
54. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. *Hypertension*. 1986;8:37-44.
55. Pohl U, Ogilvie A, Lamontagne D, Busse R. Potent effects of AP3A and AP4A on coronary resistance and autacoid release of intact rabbit hearts. *Am J Physiol*. 1991;260:H1692-7.
56. Prescott M, Milne AD, McLennan AG. Characterization of the bis(5'-nucleosidyl) tetraphosphate pyrophosphohydrolase from encysted embryos of the brine shrimp *Artemia*. *Biochem J*. 1989;259:831-8.
57. Ralevic V, Hoyle CH, Burnstock G. Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. *J Physiol*. 1995;483:703-13.
58. Ralevic V, Burnstock G. Discrimination by PPADS between endothelial P2Y- and P2U-purinoceptors in the rat isolated mesenteric arterial bed. *Br J Pharmacol*. 1996;118:428-34.
59. Redon J, Batlle D. Regulation of intracellular pH in the spontaneously hypertensive rat. Role of bicarbonate-dependent transporters. *Hypertension*. 1994;23:503-12.
60. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. *Am J Physiol*. 1986;250:H1145-9.

61. Rubino A, Burnstock G. Possible role of diadenosine polyphosphates as modulators of cardiac sensory-motor neurotransmission in guinea-pigs. *J Physiol*. 1996;495:515-23.
62. Schluter H, Offers E, Bruggemann G, van der Giet M, Tepel M, Nordhoff E, Karas M, Spieker C, Witzel H, Zidek W. Diadenosine phosphates and the physiological control of blood pressure. *Nature*. 1994;367:186-8.
63. Schluter H, Tepel M, Zidek W. Vascular actions of diadenosine phosphates. *J Auton Pharmacol*. 1996;16:357-62.
64. Schluter H, Grobeta I, Bachmann J, Kaufmann R, van der Giet M, Tepel M, Nofer JR, Assmann G, Karas M, Jankowski J, Zidek W. Adenosine(5') oligophospho-(5') guanosines and guanosine(5') oligophospho-(5') guanosines in human platelets. *J Clin Invest*. 1998;101:682-8.
65. Schulze-Lohoff E, Zanner S, Ogilvie A, Sterzel RB. Vasoactive diadenosine polyphosphates promote growth of cultured renal mesangial cells. *Hypertension*. 1995;26:899-904.
66. Stavrou BM, Sheridan DJ, Flores NA. Contribution of nitric oxide and prostanoids to the cardiac electrophysiological and coronary vasomotor effects of diadenosine polyphosphates. *J Pharmacol Exp Ther*. 2001;298:531-8.
67. Steinmetz M, Bierer S, Hollah P, Rahn KH, Schlatter E. Heterogenous vascular effects of AP5A in different rat resistance arteries are due to heterogenous distribution of P2X and P2Y(1) purinoceptors. *J Pharmacol Exp Ther*. 2000;294:1182-7.
68. Steinmetz M, Schlatter E, Boudier HA, Rahn KH, De Mey JG. Diadenosine polyphosphates cause contraction and relaxation in isolated rat resistance arteries. *J Pharmacol Exp Ther*. 2000;294:1175-81.



69. Tepel M, Bachmann J, Schluter H, Zidek W. Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin-II-induced changes of calcium in vascular smooth muscle cells. *J Vasc Res.* 1996;33:132-8.
70. Tepel M, Lowe S, Nofer JR, Assmann G, Schluter H, Zidek W. Diadenosine polyphosphates regulate cytosolic calcium in human fibroblast cells by interaction with P2x purinoceptors coupled to phospholipase C. *Biochim Biophys Acta.* 1996;1312:145-50.
71. Tepel M, Heidenreich S, Schluter H, Beinlich A, Nofer JR, Walter M, Assmann G, Zidek W. Diadenosine polyphosphates induce transplasma membrane calcium influx in cultured glomerular mesangial cells. *Eur J Clin Invest.* 1996;26:1077-84.
72. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. *Circulation.* 1998;97:1195-206.
73. Turner JT, Weisman, G. A., Fedan, J. S.,. The p2 Nucleotide Receptors;. . 1998:317-359.
74. Vahlensieck U, Boknik P, Knapp J, Linck B, Muller FU, Neumann J, Herzig S, Schluter H, Zidek W, Deng MC, Scheld HH, Schmitz W. Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. *Br J Pharmacol.* 1996;119:835-44.
75. Vahlensieck U, Boknik P, Gombosova I, Huke S, Knapp J, Linck B, Luss H, Muller HL, Neumann J, Deng MC, Scheld HH, Jankowski H, Schluter H, Zidek W, Zimmermann N, Schmitz W. Inotropic effects of diadenosine tetraphosphate (AP4A) in human and animal cardiac preparations. *J Pharmacol Exp Ther.* 1999;288:805-13.
76. van der Giet M, Khattab M, Borgel J, Schluter H, Zidek W. Differential effects of diadenosine phosphates on

- purinoceptors in the rat isolated perfused kidney. *Br J Pharmacol.* 1997;120:1453-60.
77. van der Giet M, Cinkilic O, Jankowski J, Tepel M, Zidek W, Schluter H. Evidence for two different P2X-receptors mediating vasoconstriction of Ap5A and Ap6A in the isolated perfused rat kidney. *Br J Pharmacol.* 1999;127:1463-9.
78. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. *N Engl J Med.* 1990;323:27-36.
79. Vita JA, Treasure CB, Yeung AC, Vekshtein VI, Fantasia GM, Fish RD, Ganz P, Selwyn AP. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. *Circulation.* 1992;85:1390-7.
80. Wildman SS, Brown SG, King BF, Burnstock G. Selectivity of diadenosine polyphosphates for rat P2X receptor subunits. *Eur J Pharmacol.* 1999;367:119-23.
81. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. *Circulation.* 1989;80:198-205.
82. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature.* 1988;332:411-5.
83. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. *N Engl J Med.* 2000;342:101-14.